Medicine and Dentistry
Immunoglobulin
77%
Polyradiculoneuropathy
50%
Diagnosis
43%
Peripheral Nerve
40%
Apoplexy
37%
Weakness
36%
Symptom
32%
Guillain-Barré Syndrome
30%
Neurology
29%
Meta-Analysis
29%
Prospective Cohort Study
29%
Chronic Inflammatory Demyelinating Polyneuropathy
29%
Percutaneous Thrombectomy
29%
Myasthenia gravis
29%
Infection
26%
Disease Course
25%
Muscle Strength
24%
Disease
22%
Combination Therapy
21%
Brain Ischemia
20%
Myopathy
19%
Histopathology
19%
Rehabilitation Engineering
19%
Plasma Exchange
19%
Neurologic Disease
18%
Subcutaneous Injection
18%
Electrodiagnosis
16%
Cohort Analysis
15%
Cohort Study
15%
Cohort Effect
14%
Odds Ratio
14%
Quality of Life
14%
Electromyography
13%
Outpatient
11%
Muscle Weakness
11%
Severe Acute Respiratory Syndrome Coronavirus 2
11%
Respiratory Failure
11%
Electrophysiology
11%
Observational Study
10%
Blood Clot Lysis
10%
Transient Ischemic Attack
10%
Disease Severity
10%
Maintenance Therapy
10%
Drug Megadose
9%
Neurosarcoidosis
9%
Intravenous Drug Administration
9%
Health Care Cost
9%
Antiplatelet
9%
Sarcoidosis
9%
Eculizumab
9%
Neuroscience
Intravenous Immunoglobulin
100%
Polyneuropathy
50%
Peripheral Neuropathy
40%
Peripheral Nerve
37%
Electrodiagnosis
32%
Myasthenia gravis
29%
Nerve Conduction Study
22%
Electromyography
22%
Muscle Disorder
20%
Guillain-Barre Syndrome
19%
Histopathology
19%
Eculizumab
19%
Epileptic Absence
14%
SARS Coronavirus
12%
Cerebral Hemorrhage
11%
Alteplase
11%
Magnetic Resonance Imaging
10%
Neurological Disorder
10%
Cholinergic Receptor Antibody
10%
Coronavirus
9%
Cognitive Disorders
9%
Myelitis
9%
Transverse Myelitis
9%
Human Immunoglobulin
9%
Meta-Analysis
9%
Coronavirinae
9%
Skeletal Muscle
9%
Electromyography
9%
Sarcoidosis
9%
Leukocyte
9%
Placebo
9%
Basal Lamina
8%
Immunotherapy
8%
Immunoglobulin G
6%
Electrophysiology
6%
Glucocorticoid
6%
Ganglioside Antibody
6%
Middle Cerebral Artery
5%
Hematoma
5%
Pharmacology, Toxicology and Pharmaceutical Science
Polyradiculoneuropathy
38%
Syndrome
38%
Myasthenia gravis
29%
Immunoglobulin
29%
Symptom
24%
Guillain Barre Syndrome
19%
Prospective Cohort Study
19%
Subcutaneous Injection
18%
Chronic Inflammatory Demyelinating Polyneuropathy
16%
Infection
12%
Adverse Event
11%
Cerebrovascular Accident
10%
Placebo
9%
Human Immunoglobulin
9%
Myopathy
9%
Motor Neuropathy
9%
Polyneuropathy
9%
Combination Therapy
9%
Sodium Valproate
9%
Intravenous Therapy
9%
Brain Disease
9%
Antiplatelet
9%
Cholinergic Receptor Antibody
9%
Eculizumab
9%
Inflammation
6%
